There are also diseases where shrink-wrapped μMonolayers engrafted into epithelial layers could provide new therapeutic options, such as the delivery of airway cells genetically edited to restore cystic fibrosis transmembrane conductance regulator (CFTR) function for cystic fibrosis patients, or delivering alveolar type II epithelial cells to damaged distal regions post COVID-19 infection. The gene discussed is CFTR; the disease is cystic fibrosis.